MedPath

Ethris Reports Successful Phase 1 Results for Novel Nasal mRNA Therapy ETH47 in Asthma Treatment

• Ethris's ETH47, a nasal mRNA therapeutic encoding interferon lambda, demonstrated successful protein expression and target engagement in Phase 1 clinical trials with healthy volunteers.

• The treatment showed a favorable safety profile across all dose levels, with no serious adverse events reported and no systemic bioavailability observed.

• Based on positive results, Ethris plans to advance ETH47 to Phase 2a clinical trials in Q2 2025, focusing on reducing post-rhinovirus symptoms in asthma patients.

Ethris GmbH has achieved a significant breakthrough in mRNA therapeutics with positive Phase 1 clinical trial results for ETH47, its lead candidate for uncontrolled asthma. The trial marks a crucial step forward in developing targeted RNA therapeutics for respiratory conditions.
The study, involving 40 healthy volunteers, demonstrated that nasally administered ETH47 successfully produced interferon lambda (IFNλ), a key protein involved in viral immunity within the respiratory tract. The results were presented by Dr. Thomas Langenickel, Chief Medical Officer at Ethris, at the mRNA-Based Therapeutics Summit Europe in Frankfurt, Germany.

Safety and Efficacy Profile

The Phase 1 trial revealed a robust safety profile for ETH47, with no serious or severe adverse events reported across all tested dose levels. Importantly, the treatment showed no observable systemic bioavailability, suggesting its effects remain localized to the respiratory tract. The study demonstrated dose-dependent interferon lambda protein expression, confirming successful target engagement.

Innovative Technology Platform

ETH47 represents a validation of Ethris's proprietary SNIM® and SNaP® technology platforms, designed specifically for respiratory tract mRNA delivery. This achievement marks the first clinical validation of the company's targeted RNA therapeutic approach, demonstrating successful local protein production following nasal administration.

Clinical Development Path

"These positive Phase 1 results reinforce the promise of ETH47 as a potentially safe and transformative treatment option for asthma patients," stated Dr. Langenickel. The company has outlined plans to initiate a Phase 2a clinical trial in the second quarter of 2025, which will evaluate ETH47's effectiveness in reducing symptoms following rhinovirus infection in asthma patients.

Therapeutic Implications

The development of ETH47 addresses a critical need in asthma treatment by targeting the upstream triggers of asthma exacerbations. By focusing on the production of interferon lambda, the therapy aims to enhance viral immunity in the respiratory tract, potentially offering a new approach to preventing and managing asthma exacerbations.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Ethris's Inhaled mRNA Therapy Shows Promise in Phase 1 Asthma Trial

Munich-based Ethris has reported positive Phase 1 results for ETH47, an inhaled mRNA therapy targeting uncontrolled asthma. The treatment demonstrated safety and tolerability across all dose levels in 40 healthy volunteers, successfully inducing targeted immune responses in the respiratory tract without systemic exposure.

ENA Respiratory's Novel Intranasal Antiviral Immune Enhancer Shows Promise in Phase Ib Trial

ENA Respiratory has successfully completed Phase Ib dosing of INNA-051 dry powder formulation in adults over 60, demonstrating good tolerability and activation of innate immune pathways. The new formulation offers improved stability with a two-year shelf life at room temperature, positioning it as a potential seasonal preventive treatment for viral respiratory infections.

Hoth Therapeutics' HT-001 Demonstrates 100% Success in Phase 2a Trial for Cancer Treatment Skin Toxicities

Hoth Therapeutics' HT-001 achieved a 100% success rate in a Phase 2a trial, significantly improving skin toxicities caused by EGFR inhibitors in cancer patients.
The CLEER-001 trial data showed that all patients achieved the primary efficacy endpoint, with notable improvements in skin toxicity by the six-week mark.

Nurix Therapeutics' NX-5948 Receives EMA PRIME Designation for Relapsed/Refractory CLL

Nurix Therapeutics' NX-5948, a BTK degrader, has been granted PRIME designation by the EMA for relapsed or refractory chronic lymphocytic leukemia (CLL).
The PRIME designation aims to expedite the development and evaluation of NX-5948, offering enhanced support for Nurix's development plans.

MIRA Pharmaceuticals Advances Ketamir-2 for Neuropathic Pain with FDA Application and Clinical Trial Plans

MIRA Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for Ketamir-2, an oral ketamine analog, to treat neuropathic pain.
Preclinical studies of Ketamir-2 demonstrated 100% pain reversal in validated neuropathic pain models and showed a favorable safety profile with no observed adverse effects.

Tharimmune's TH104 Receives Positive EMA Feedback for Pruritus in Primary Biliary Cholangitis

Tharimmune received positive feedback from the EMA regarding its Phase 2 and Phase 3 clinical program for TH104, targeting moderate-to-severe pruritus in primary biliary cholangitis (PBC).
The EMA indicated that a hybrid application under Article 10(3) is acceptable, potentially allowing the use of existing non-clinical and safety data for TH104.

EMA Endorses Tharimmune's TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

The EMA has endorsed Tharimmune's TH104 clinical program for chronic pruritus in primary biliary cholangitis (PBC), supporting the company's development strategy.
The agency has accepted the Article 10(3) hybrid application, potentially streamlining the approval process by leveraging existing safety data.

MaaT Pharma Completes Enrollment in Phase 3 Trial of MaaT013 for Acute Graft-versus-Host Disease

MaaT Pharma has completed recruitment for its Phase 3 ARES trial evaluating MaaT013 in patients with steroid and ruxolitinib-refractory acute Graft-versus-Host Disease.
The ARES trial is a multicenter, European, open-label, single-arm study assessing the safety and efficacy of MaaT013, with topline results expected in January 2025.

Tectonic Therapeutic's TX45 Shows Promise in Phase Ia Trial for Pulmonary Hypertension

Tectonic Therapeutic reported positive topline data from its Phase Ia trial of TX45 for Group 2 pulmonary hypertension with preserved ejection fraction (PH-HFpEF).
The trial demonstrated that TX45 was safe and well-tolerated in healthy subjects, with minimal adverse events and no immune-mediated clearance observed.

Hoth Therapeutics Expands HT-001 Phase 2a Trial for EGFRi-Induced Skin Toxicities

Hoth Therapeutics has received IRB approval from Montefiore Medical Center and Dana-Farber Cancer Institute for its Phase 2a trial of HT-001.
The Phase 2a trial will assess the efficacy, safety, and tolerability of topical HT-001 for skin toxicities related to EGFR inhibitor treatments.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy